FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21

被引:13
|
作者
Yamada, Kayo [1 ]
Ono, Motoharu [1 ]
Bensaddek, Dalila [1 ]
Lamond, Angus I. [1 ]
Rocha, Sonia [1 ]
机构
[1] Univ Dundee, Ctr Gene Regulat & Express, Coll Life Sci, Dundee, Scotland
基金
英国惠康基金;
关键词
DNA damage; FMN2; cancer; cell cycle; hypoxia; p14ARF; p21; p53; ARF TUMOR-SUPPRESSOR; NF-KAPPA-B; P53; TRANSACTIVATION; IDENTIFICATION; DEGRADATION; NETWORKS; REVEALS; CANCER; ATR;
D O I
10.4161/cc.25511
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We have identified the human FMN2 gene as a novel target regulated by induction of p14ARF and by multiple other stress responses, including DNA damage and hypoxia, which have in common activation of cell cycle arrest. We showed that increased expression of the FMN2 gene following p14ARF induction is caused, at the transcriptional level, by relief of repression by RelA and E2F1, which, under non-induced conditions, bind the FMN2 promoter. Increased FMN2 protein levels promote cell cycle arrest by inhibiting the degradation of p21, and our data show that control of p21 stability is a key part of the mechanism that regulates p21 induction. Consistent with this model, we have shown that transient expression of exogenous FMN2 protein alone is sufficient to increase p21 protein levels in cells, without altering p21 mRNA levels. Here, we provide additional evidence for the role of the N terminus of FMN2 as being the important domain required for p21 stability. In addition, we also investigate the role of RelA's threonine 505 residue in the control of FMN2. Our results identify FMN2 as a crucial protein involved in the control of p21.
引用
收藏
页码:2348 / 2354
页数:7
相关论文
共 50 条
  • [31] Cyclin-dependent kinase inhibitor p21 and proliferative marker ki67 in colonic carcinoma
    Kumar, Sanjay
    Singh, Neha
    Kataria, Sant Prakash
    Kandoi, Shruti
    Verma, Meena
    Sen, Rajeev
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (04) : 915 - 920
  • [32] Establishment of a Dog Model for the p53 Family Pathway and Identification of a Novel Isoform of p21 Cyclin-Dependent Kinase Inhibitor
    Zhang, Jin
    Chen, Xiangling
    Kent, Michael S.
    Rodriguez, Carlos O.
    Chen, Xinbin
    MOLECULAR CANCER RESEARCH, 2009, 7 (01) : 67 - 78
  • [33] Transcriptional regulation of cyclin-dependent kinase inhibitor 1A (P21) by the transcription factor AP-2γ
    Scibetta, A. G.
    Canosa, M.
    Hurst, H. C.
    BREAST CANCER RESEARCH, 2010, 12 : S7 - S7
  • [34] Transcriptional regulation of cyclin-dependent kinase inhibitor 1A (P21) by the transcription factor AP-2γ
    AG Scibetta
    M Canosa
    HC Hurst
    Breast Cancer Research, 12
  • [35] The role of the cyclin-dependent kinase inhibitor p21 in p53-dependent and -independent leukemic cell differentiation.
    Ehinger, M
    Rolfsson, O
    Chylicki, K
    Gullberg, U
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 61 - 61
  • [36] Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury
    Yang, ZY
    Simari, RD
    Perkins, ND
    San, H
    Gordon, D
    Nabel, GJ
    Nabel, EG
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7905 - 7910
  • [37] IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
    Hobeika, AC
    Subramaniam, PS
    Johnson, HM
    ONCOGENE, 1997, 14 (10) : 1165 - 1170
  • [38] Interaction of the cyclin-dependent kinase inhibitor p21 with PCNA: A link between cell cycle and DNA repair
    Cayrol, C
    Ducommun, B
    M S-MEDECINE SCIENCES, 1997, 13 (11): : 1259 - 1265
  • [39] Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1)
    Fukui, R
    Shibata, N
    Kohbayashi, E
    Amakawa, M
    Furutama, D
    Hoshiga, M
    Negoro, N
    Nakakouji, T
    Ii, M
    Ishihara, T
    Ohsawa, N
    ATHEROSCLEROSIS, 1997, 132 (01) : 53 - 59
  • [40] Improved proliferation of DMD myoblasts by silencing the cyclin-dependent kinase inhibitor p21 -: a new therapeutic approach
    Kliche, A
    Moers, AV
    Endesfelder, S
    Lochmüller, H
    Speer, A
    NEUROMUSCULAR DISORDERS, 2005, 15 (9-10) : 701 - 701